Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Sponsor: Bellicum Pharmaceuticals
A PHASE1 clinical study on Hematologic Neoplasms and Leukemia, this trial is ongoing. The trial is conducted by Bellicum Pharmaceuticals and has accumulated 14 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Feb 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE1
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
Dec 2018 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE1
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bellicum Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .